| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| host | mouse |
| isotype | IgG2b |
| clonality | monoclonal |
| concentration | 1 mg/mL |
| applications | ICC/IF, WB |
| reactivity | p84 |
| available sizes | 100 µg |
mouse anti-p84 monoclonal antibody (5E9) 9573
$503.00
Antibody summary
- Mouse monoclonal to p84
- Suitable for: WB,ICC/IF,IHC-P,IP,ChIP,IHC
- Isotype: IgG2b
- 100 µg
mouse anti-p84 monoclonal antibody (5E9) 9573
| antibody |
|---|
| Tested applications WB,IHC,IHC,ICC/IF |
| Recommended dilutions Immunoblotting, immunoprecipitation, and Immunofluorescence: use at 0.5-2 ug/mL.In immunoblots, a band of 84 kD is detected. Positive controls: Lysates of Molt 4, HeLa, or Raji cells. |
| Immunogen Fusion protein containing amino acids 15-374 of human p84 expressed in E. coli. |
| Size and concentration 100µg and lot specific |
| Form liquid |
| Storage Instructions This antibody is stable for at least one (1) year at -70°C. Avoid multiple freeze- thaw cycles. |
| Storage buffer PBS, pH 7.4. |
| Purity protein affinty purification |
| Clonality monoclonal |
| Isotype IgG2b |
| Compatible secondaries goat anti-mouse IgG, H&L chain specific, peroxidase conjugated polyclonal antibody 5486 goat anti-mouse IgG, H&L chain specific, biotin conjugated, Conjugate polyclonal antibody 2685 goat anti-mouse IgG, H&L chain specific, FITC conjugated polyclonal antibody 7854 goat anti-mouse IgG, H&L chain specific, peroxidase conjugated polyclonal antibody, crossabsorbed 1706 goat anti-mouse IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1716 goat anti-mouse IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1721 |
| Isotype control Mouse monocolonal IgG2b - Isotype Control |
| target relevance |
|---|
| Protein names THO complex subunit 1 (Tho1) (Nuclear matrix protein p84) (p84N5) (hTREX84) |
| Gene names THOC1,THOC1 HPR1 |
| Mass 75666Da |
| Function Required for efficient export of polyadenylated RNA. Acts as component of the THO subcomplex of the TREX complex which is thought to couple mRNA transcription, processing and nuclear export, and which specifically associates with spliced mRNA and not with unspliced pre-mRNA. TREX is recruited to spliced mRNAs by a transcription-independent mechanism, binds to mRNA upstream of the exon-junction complex (EJC) and is recruited in a splicing- and cap-dependent manner to a region near the 5' end of the mRNA where it functions in mRNA export to the cytoplasm via the TAP/NFX1 pathway. The TREX complex is essential for the export of Kaposi's sarcoma-associated herpesvirus (KSHV) intronless mRNAs and infectious virus production. Regulates transcriptional elongation of a subset of genes. Involved in genome stability by preventing co-transcriptional R-loop formation. May play a role in hair cell formation, hence may be involved in hearing (By similarity).; Participates in an apoptotic pathway which is characterized by activation of caspase-6, increases in the expression of BAK1 and BCL2L1 and activation of NF-kappa-B. This pathway does not require p53/TP53, nor does the presence of p53/TP53 affect the efficiency of cell killing. Activates a G2/M cell cycle checkpoint prior to the onset of apoptosis. Apoptosis is inhibited by association with RB1. |
| Subellular location [Isoform 1]: Nucleus speckle. Nucleus, nucleoplasm. Nucleus matrix. Cytoplasm. Note=Can shuttle between the nucleus and cytoplasm. Nuclear localization is required for induction of apoptotic cell death. Translocates to the cytoplasm during the early phase of apoptosis execution.; [Isoform 2]: Cytoplasm. |
| Tissues Ubiquitous. Expressed in various cancer cell lines. Expressed at very low levels in normal breast epithelial cells and highly expressed in breast tumors. Expression is strongly associated with an aggressive phenotype of breast tumors and expression correlates with tumor size and the metastatic state of the tumor progression. |
| Structure Component of the THO complex, which is composed of THOC1, THOC2, THOC3, THOC5, THOC6 and THOC7; together with at least ALYREF/THOC4, DDX39B, SARNP/CIP29 and CHTOP, THO forms the transcription/export (TREX) complex which seems to have a dynamic structure involving ATP-dependent remodeling. Binds to the hypophosphorylated form of RB1. Interacts with THOC2, DDX39B and RNA polymerase II. Interacts with THOC5 (By similarity). Interacts with LUZP4. |
| Post-translational modification Expression is altered specifically during apoptosis and is accompanied by the appearance of novel forms with smaller apparent molecular mass.; Polyubiquitinated, leading to proteasomal degradation; probably involves NEDD4. |
| Involvement in disease DISEASE: Deafness, autosomal dominant, 86 (DFNA86) [MIM:620280]: A form of non-syndromic, sensorineural hearing loss. Sensorineural hearing loss results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA86 is characterized by progressive, bilateral hearing loss that is most predominant in the high frequencies, begins mildly during the fourth decade and gradually progresses to severe-to-profound deafness in the seventh and eighth decades. Affected subjects have tinnitus, while vestibular dysfunction or other clinical abnormalities are not present. Note=The disease is caused by variants affecting the gene represented in this entry. |
| Target Relevance information above includes information from UniProt accession: Q96FV9 |
| The UniProt Consortium |
Data
 |
| Nuclear Matrix Protein p84 antibody [5E10] detects Nuclear Matrix Protein p84 protein at nucleus by immunohistochemical analysis.Sample: Paraffin-embedded human breast carcinoma.Nuclear Matrix Protein p84 stained by Nuclear Matrix Protein p84 antibody [5E10] (9573) diluted at 1:200.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min |
 |
| Detection of human p84/N5 in nuclear fraction by anti-p84/N5 5E10 monoclonal antibody (9573) in western blot experiment. Lane 1: total lysate, Lane 2: cytoplasmic fraction, Lane 3: membrane fraction, Lane 4: nuclear fraction. |
 |
| Nuclear Matrix Protein p84 antibody [5E10] detects Nuclear Matrix Protein p84 protein at nucleus by immunofluorescent analysis.Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: Nuclear Matrix Protein p84 stained by Nuclear Matrix Protein p84 antibody [5E10] (9573) diluted at 1:500.Red: phalloidin, a cytoskeleton marker, diluted at 1:100. |
 |
| p84 antibody [5E10] immunoprecipitates p84 protein in IP experiments. IP Sample: HepG2 whole cell lysate/extract A : 30 µg whole cell lysate/extract of p84 protein expressing HepG2 cells B : Control with 3 µg of pre-immune mouse IgG C : Immunoprecipitation of p84 by 3 µg of p84 antibody [5E10] (9573) 7.5% SDS-PAGE The immunoprecipitated p84 protein was detected by p84 antibody [5E10] (9573) diluted at 1 : 1000. EasyBlot anti-rabbit IgG (HRP) was used as a secondary reagent. |
 |
| Sample (30 µg of whole cell lysate) A: HeLa B: HeLa nucleus 7.5% SDS PAGE 9573 diluted at 1:1000 The HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody. |
 |
| Sample (50 µg of whole cell lysate) A: mouse Cerebellum 7.5% SDS PAGE 9573 diluted at 1:1000 The HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody. |
 |
| Sample (whole cell lysate) A: 293T 20ug B: 293T 10ug C: 293T 5ug 7.5% SDS PAGE 9573 diluted at 1:1000 The HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody. |
 |
| Nuclear Matrix Protein p84 antibody [5E10] detects Nuclear Matrix Protein p84 protein at nucleus by immunohistochemical analysis.Sample: Paraffin-embedded human lung cancer.Nuclear Matrix Protein p84 stained by Nuclear Matrix Protein p84 antibody [5E10] (9573) diluted at 1:100.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min |
 |
| Various whole cell extracts (30 µg) were separated by 7.5% SDS-PAGE, and the membrane was blotted with Nuclear Matrix Protein p84 antibody [5E10] (9573) diluted at 1:500. The HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody. |
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.There are 158 publications in our database for this antibody or clone. Here are the latest 5, for more click below.
| pmid | title | authors | citation |
|---|---|---|---|
| 37885910 | A Knock-In Mouse Model of the Gcm2 Variant p.Y392S Develops Normal Parathyroid Glands | Parekh VI, Brinster LR, Guan B, Simonds WF, Weinstein LS, Agarwal SK. | J Endocr Soc. 2023 Oct 6;7(11):bvad126. doi: 10.1210/jendso/bvad126. eCollection 2023 Oct 9. |
| 37790327 | Increased AID Results in Mutations at the CRLF2 Locus Implicated in Latin American ALL Health Disparities | Pannunzio N, Rangel V, Sterrenberg J, Garawi A, Mezcord V, Folkerts M, Caulderon S, Wang J, Soyfer E, Eng O, Valerin J, Tanjasiri S, Quintero-Rivera F, Masri S, Seldin M, Frock R, Fleischman A. | Res Sq [Preprint]. 2023 Sep 11:rs.3.rs-3332673. doi: 10.21203/rs.3.rs-3332673/v1. |
| 37267101 | Liver and muscle circadian clocks cooperate to support glucose tolerance in mice | Smith JG, Koronowski KB, Mortimer T, Sato T, Greco CM, Petrus P, Verlande A, Chen S, Samad M, Deyneka E, Mathur L, Blazev R, Molendijk J, Kumar A, Deryagin O, Vaca-Dempere M, Sica V, Liu P, Orlando V, Parker BL, Baldi P, Welz PS, Jang C, Masri S, Benitah SA, Mu?oz-C?noves P, Sassone-Corsi P. | Cell Rep. 2023 Jun 27;42(6):112588. doi: 10.1016/j.celrep.2023.112588. Epub 2023 Jun 1. |
| 36973248 | Time-of-day defines NAD(+) efficacy to treat diet-induced metabolic disease by synchronizing the hepatic clock in mice | Escalante-Covarrubias Q, Mendoza-Viveros L, Gonz?lez-Su?rez M, Sitten-Olea R, Vel?zquez-Villegas LA, Becerril-P?rez F, Pacheco-Bernal I, Carre?o-V?zquez E, Mass-S?nchez P, Bustamante-Zepeda M, Orozco-Sol?s R, Aguilar-Arnal L. | Nat Commun. 2023 Mar 27;14(1):1685. doi: 10.1038/s41467-023-37286-2. |
| 36646704 | Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis | Arimoto KI, Miyauchi S, Troutman TD, Zhang Y, Liu M, Stoner SA, Davis AG, Fan JB, Huang YJ, Yan M, Glass CK, Zhang DE. | Nat Commun. 2023 Jan 17;14(1):251. doi: 10.1038/s41467-022-35348-5. |
Protocols
| relevant to this product |
|---|
| Western blot IHC ICC |
Documents
| # | |||
|---|---|---|---|
| Please enter your product and batch number here to retrieve - product datasheet, SDS, and QC information. | |||
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.